|
1
|
Hoffman RM, Meisner AL, Barry M, Shah SK,
Zeliadt SB and Wiggins CL: Trends in United States prostate cancer
incidence rates by age and stage, 1995-2012. Cancer Epidemiol
Biomarkers Prev. 25:259–263. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hayes JH and Barry MJ: Screening for
prostate cancer with the prostate-specific antigen test: A review
of current evidence. JAMA. 311:1143–1149. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Winter A, Sirri E, Jansen L, Wawroschek F,
Kieschke J, Castro FA, Krilaviciute A, Holleczek B, Emrich K,
Waldmann A, et al: Comparison of prostate cancer survival in
Germany and the USA: Can differences be attributed to differences
in stage distributions? BJU Int. 119:550–559. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wong MC, Goggins WB, Wang HH, Fung FD,
Leung C, Wong SY, Ng CF and Sung JJ: Global incidence and mortality
for prostate cancer: Analysis of temporal patterns and trends in 36
countries. Eur Urol. 70:862–874. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Reulen RC, de Vogel S, Zhong W, Zhong Z,
Xie LP, Hu Z, Deng Y, Yang K, Liang Y, Zeng X, et al: Physical
activity and risk of prostate and bladder cancer in China: The
South and East China case-control study on prostate and bladder
cancer. PLoS One. 12(e0178613)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Qi JL, Wang LJ, Zhou MG, Liu YN, Liu JM,
Liu SW, Zeng XY and Yin P: Disease burden of prostate cancer among
men in China, from 1990 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi.
37:778–782. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
7
|
Lin C, Bai S, Du T, Lai Y, Chen X, Peng S,
Ma X, Wu W, Guo Z and Huang H: Polo-like kinase 3 is associated
with poor prognosis and regulates proliferation and metastasis in
prostate cancer. Cancer Manag Res. 11:1517–1524. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Downing A, Wright P, Hounsome L, Selby P,
Wilding S, Watson E, Wagland R, Kind P, Donnelly DW, Butcher H, et
al: Quality of life in men living with advanced and localised
prostate cancer in the UK: A population-based study. Lancet Oncol.
20:436–447. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Park SH, Eber MR and Shiozawa Y: Models of
prostate cancer bone metastasis. Methods Mol Biol. 1914:295–308.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liu B, Li J and Cairns MJ: Identifying
miRNAs, targets and functions. Brief Bioinform. 15:1–19.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang Q, Zhang K, Zhang C, Ge H, Yin Y,
Feng H and Hu R: MicroRNAs as big regulators of neural
stem/progenitor cell proliferation, differentiation and migration:
A potential treatment for stroke. Curr Pharm Des. 23:2252–2257.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu H, Cao B, Zhao Y, Liang H and Liu X:
Upregulated miR-221/222 promotes cell proliferation and invasion
and is associated with invasive features in retinoblastoma. Cancer
Biomark. 22:621–629. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Peng P, Chen T, Wang Q, Zhang Y, Zheng F,
Huang S, Tang Y, Yang C, Ding W, Ren D, et al: Decreased miR-218-5p
levels as a serum biomarker in bone metastasis of prostate cancer.
Oncol Res Treat. 42:165–185. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nagahama Y and Fukui T: Dementia with Lewy
bodies presenting as frontotemporal dementia phenotype.
Psychogeriatrics. 19:505–509. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Moya L, Meijer J, Schubert S, Matin F and
Batra J: Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289
expression as biomarker for prostate cancer diagnosis. Int J Mol
Sci. 20(1154)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Malla RR, Kumari S, Gavara MM, Badana AK,
Gugalavath S, Kumar DKG and Rokkam P: A perspective on the
diagnostics, prognostics, and therapeutics of microRNAs of
triple-negative breast cancer. Biophys Rev. 11:227–234.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang L, Belaguli N and Berger DH: MicroRNA
and colorectal cancer. World J Surg. 33:638–646. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Foj L and Filella X: Identification of
potential miRNAs biomarkers for high-grade prostate cancer by
integrated bioinformatics analysis. Pathol Oncol Res. 25:1445–1456.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Quiroz-Munoz M, Izadmehr S, Arumugam D,
Wong B, Kirschenbaum A and Levine AC: Mechanisms of osteoblastic
bone metastasis in prostate cancer: Role of prostatic acid
phosphatase. J Endocr Soc. 3:655–664. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Loberg RD, Logothetis CJ, Keller ET and
Pienta KJ: Pathogenesis and treatment of prostate cancer bone
metastases: Targeting the lethal phenotype. J Clin Oncol.
23:8232–8241. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kelly SP, Anderson WF, Rosenberg PS and
Cook MB: Past, current, and future incidence rates and burden of
metastatic prostate cancer in the United States. Eur Urol Focus.
4:121–127. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Costa-Pinheiro P, Montezuma D, Henrique R
and Jeronimo C: Diagnostic and prognostic epigenetic biomarkers in
cancer. Epigenomics. 7:1003–1015. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Quan Y, Huang X and Quan X: Expression of
miRNA-206 and miRNA-145 in breast cancer and correlation with
prognosis. Oncol Lett. 16:6638–6642. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nan P, Niu Y, Wang X and Li Q: MiR-29a
function as tumor suppressor in cervical cancer by targeting SIRT1
and predict patient prognosis. Onco Targets Ther. 12:6917–6925.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Casanova-Salas I, Rubio-Briones J,
Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A,
Rubio L, Ramírez-Backhaus M, Armiñán A, et al: Identification of
miR-187 and miR-182 as biomarkers of early diagnosis and prognosis
in patients with prostate cancer treated with radical
prostatectomy. J Urol. 192:252–259. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Goto Y, Kurozumi A, Arai T, Nohata N,
Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, et al:
Impact of novel miR-145-3p regulatory networks on survival in
patients with castration-resistant prostate cancer. Br J Cancer.
117:409–420. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sun Y, Mei H, Xu C, Tang H and Wei W:
Circulating microRNA-339-5p and -21 in plasma as an early detection
predictors of lung adenocarcinoma. Pathol Res Pract. 214:119–125.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang YL, Chen CM, Wang XM and Wang L:
Effects of miR-339-5p on invasion and prognosis of hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol. 40:51–56.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gan CZ, Li G, Luo QS and Li HM: MiR-339-5p
downregulation contributes to Taxol resistance in small-cell lung
cancer by targeting α1,2-fucosyltransferase 1. IUBMB Life.
69:841–849. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
32
|
Shan W, Li J, Bai Y and Lu X: MiR-339-5p
inhibits migration and invasion in ovarian cancer cell lines by
targeting NACC1 and BCL6. Tumour Biol. 37:5203–5211.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Jansson MD, Damas ND, Lees M, Jacobsen A
and Lund AH: MiR-339-5p regulates the p53 tumor-suppressor pathway
by targeting MDM2. Oncogene. 34:1908–1918. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhou C, Liu G, Wang L, Lu Y, Yuan L, Zheng
L, Chen F, Peng F and Li X: MiR-339-5p regulates the growth, colony
formation and metastasis of colorectal cancer cells by targeting
PRL-1. PLoS One. 8(e63142)2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Luo A, Zhou X, Shi X, Zhao Y, Men Y, Chang
X, Chen H, Ding F, Li Y, Su D, et al: Exosome-derived miR-339-5p
mediates radiosensitivity by targeting Cdc25A in locally advanced
esophageal squamous cell carcinoma. Oncogene. 38:4990–5006.
2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li P, Liu H, Li Y, Wang Y, Zhao L and Wang
H: MiR-339-5p inhibits lung adenocarcinoma invasion and migration
by directly targeting BCL6. Oncol Lett. 16:5785–5790.
2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sun X, Liu H, Li T and Qin L:
MicroRNA-339-5p inhibits cell proliferation of acute myeloid
leukaemia by directly targeting SOX4. Mol Med Rep. 18:5261–5269.
2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Grimm D, Bauer J, Wise P, Krüger M,
Simonsen U, Wehland M, Infanger M and Corydon TJ: The role of SOX
family members in solid tumours and metastasis. Semin Cancer Biol.
S1044-579X(18)30141-X:2019.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
39
|
Moran JD, Kim HH, Li Z and Moreno CS: SOX4
regulates invasion of bladder cancer cells via repression of WNT5a.
Int J Oncol. 55:359–370. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu Y, Zeng S, Jiang X, Lai D and Su Z:
SOX4 induces tumor invasion by targeting EMT-related pathway in
prostate cancer. Tumour Biol. 39(1010428317694539)2017.PubMed/NCBI View Article : Google Scholar
|
